From YMB

New Post Public Reply Private Reply Replies (1) Message Board
FBCoach18 CTMedic #56614
1,174
From YMB Been meaning to share my perspective for a long time on this board, and now here goes.

As background: I am relatively new to investing, and have been working with FDA as a regulatory professional representing small biotechs for over 10 years. I have worked on multiple new COVID drugs in the past six months.

I agree with the sentiment expressed by cool heads on this board that there is too much pressure for things to happen quickly. In my experience, the best way to succeed with FDA (and other regulatory bodies) is to approach them openly and transparently, and not to DEMAND approval but to COLLABORATE on approval. My impression is that Cytodyn is doing this now, by asking FDA and MHRA for their opinion on the currently available data. Based on my experience, I believe the interest in the severe/critical study readout from both agencies is very a strong signal of their intention to act quickly if results are positive.

Another point I think is very important for Cytodyn in the COVID game, which many others have expressed, is that APPROVAL is different than AUTHORIZATION. Approval is a much, much better goal and worth waiting for. I too have been frustrated by the EUA for remdesivir, but as a huge company they have the resources to enroll many thousands of patients to reach for statistical significance with a tiny effect size. The fact that any effect was visible in the small M/M trial with Leronlimab is promising. It is my opinion that the willingness of FDA to COLLABORATE on a Phase III study for the moderate population speaks to their intent to APPROVE the drug for this population, if endpoints are met.

The bottom line is that the COVID application could absolutely still fail. I think it is very unlikely, especially after hearing the physicians on the call yesterday, but anecdotal data is just that - anecdotal. Until the S/C readout is available, patience will be the only investment strategy that is rewarded with this stock. However, the science here is strong, and the observation that patients recovered from ARDS/sepsis/other severe conditions when administered Leronlimab (and decrease in key cytokines was concurrent) is convincing enough for me.

As for the HIV BLA - I think the company has certainly had missteps along the way with the application process. I also know from experience that FDA does not grant fast track status easily. They are intentional in their selection of drugs for this designation, and Leronlimab has clearly met the bar. I think an approval for HIV could come in 6-8 months (normally 10-12 months from filing) with an 'accelerated' PDUFA date, depending on how much data has been officially 'submitted' using the rolling review process. If this happens sooner, I will be pleasantly surprised, and if not, I will wait patiently.

There is still the specter of competition, and there are many good resources to see where other drugs are in the competitive landscape. One of my favorites is updated regularly by a professional organization for regulatory affairs: https://www.raps.org/news-and-articles/news-a...cs-tracker. The most interesting, in my opinion, are Lenzilumab and Aviptadil (particularly the inhaled version). I do not own any shares of HGEN nor do I plan to, but I think they are the most significant competitor here as they are in Phase III and seem to be making significant progress with a similar-ish MoA (reduction of cytokines). As for Aviptadil/RLFTF, I do own shares and still think it is very promising, although their shareholder-facing presence has been significantly more reserved (which I tend to see as a positive) so I don't have much certainty about their progress. They may surprise everyone with a big announcement, but the inhaled version is what I find most promising from a scientific perspective, and it appears that trial is still in early stages.

I want to emphasize that, for the sake of humanity and especially the united states, I won't be disappointed if competitors 'beat us to the finish line' because it means hundreds of thousands of lives may be saved. I will simply hold for the HIV approval and take profits at that point.

However, I do think that things could quickly escalate for Cytodyn if results from the S/C are positive. This is not a new revelation for many on this board, but worth restating that at this point, those results appear to be the next significant catalyst.

I look forward to thoughtful comments/questions.

CytoDyn Inc (CYDY) Stock Research Links

CYDY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Flagship's £100M London Move to Ignite AI Ventures

Updated Category News Views 187

London Calling: Flagship's New Venture Flagship Pioneering, the brain behind bustling biotech ventures like Moderna, is planting its flag in London. They're launching Flagship Origination Lab, U.K., their first real gig outside good ol' Cambridge, Massachusetts. They're diving in headfirst, sprinkling a whopping £100 million to brew up AI-native platform companies. And...

Continue Reading
NVIDIA Faces Turbulent Storm with CEO Resignation

Updated Category News Views 5

Huang's Unexpected Exit and NVIDIA's Rocky Road Well, talk about drama in Silicon Valley. When executives start stumbling, it's not just some PR nightmare—it's a full-on crisis. NVIDIA's co-founder and CEO Jensen Huang is calling it quits, and not on some smooth, idyllic note. No, this is the kind of exit that investors dread. You’ve got affairs, security concerns,...

Continue Reading
DemandTec Leads the Pack in Retail Pricing Arena

Updated Category News Views 46

DemandTec's Climb to Retail Pricing Stardom The news hitting the streets is that DemandTec's carved out a top spot in QKS Group's SPARK Matrix™ for Intelligent Retail Pricing & Promotion Optimization for 2026. In an industry filled with slick operators and gimmicks, it takes some real chops to stand out. They've clinched this position by rolling out a platform that ties...

Continue Reading
Envision and Tsinghua Propel Climate Innovation at COP31

Updated Category News Views 87

Collaborating for a Greener Future On the bustling stage of COP31 in Antalya, Turkey, Envision Energy and Tsinghua University teamed up with the Global Alliance of Universities on Climate (GAUC) to showcase a bold agenda. Their focus transcends mere dialogue, pushing for actionable climate solutions anchored in technological innovation, academic synergy, and the dynamism...

Continue Reading
Mercari and Suruga-ya Forge U.S. Venture for Culture

Updated Category News Views 131

Japanese Pop Culture Gears Up for US Market Surge Alright, folks, what we’ve got here is another bold move in the cross-border e-commerce game. Mercari and Suruga-ya are teaming up to establish a joint venture over in the U.S. The goal? To further capitalize on the growing appetite for Japanese entertainment and hobby goods among us all stateside. Now, it’s no secret...

Continue Reading
Parallels Desktop Tops 2026 Picks for Windows on Mac

Updated Category News Views 59

Diving into the Cross-Platform Conundrum Now, I've been in the trenches long enough to know that when companies start relying on Mac computers but can't ditch their essential Windows apps, they're bound to hit a digital brick wall. Picture this—accounting, enterprise management, all that jazz that still needs Windows to function. For those jumping between these two...

Continue Reading
Insight Into Midland TX Real Estate Sales Timing

Updated Category News Views 0

How Fast Do Homes Move in Midland? This ain't my first rodeo predicting the real estate rollercoaster in Texas. Midland's housing market is one nifty beast—homes can either sell like hotcakes or just sit gathering dust. You got HelloNation pulling in DeLaura Gammage, a pro who knows the terrain like the back of her hand, to spell out the why and how long it'll take to...

Continue Reading
Terminus Ballet: A Decade of Defying Dance Norms

Updated Category News Views 35

A Dance Company's Journey of Transformation An anniversary represents more than just a celebration; it's a reminder of the road traveled. On Jan. 30, 2027, Terminus Modern Ballet Theatre will mark its 10th anniversary, encapsulating a decade of defiance against the staid conventions binding classical ballet. This isn't just about pirouettes and pliés—it's dance with a...

Continue Reading
DarioHealth's New Research Tackles Healthcare Cost Estimation

Updated Category News Views 67

Unpacking Dario's Bold Surgical Strike at ISPOR Europe Alright, folks, DarioHealth is shaking up the stage with their new methodology that could very well carve a new path in how we size up digital healthcare savings. Presented at ISPOR Europe 2026, Dario's tactic bypasses the sluggish wait on medical claims data, instead offering an evidence-driven peek at potential...

Continue Reading
Sue Egstrand to Lead Karo's Next Growth Phase

Updated Category News Views 117

A New Captain at Karo’s Helm Karo Healthcare is bracing for an exciting ride. Sue Egstrand’s appointment as the new CEO pulls the curtain on what might just be a game-changing era for the company. Set to take the wheel on January 1, 2027, Egstrand brings a heavy-hitting resume—a mash-up of pharmaceutical prowess and a deep-dive into consumer healthcare. Sue’s...

Continue Reading

Top 5 Most Recently Viewed Articles

Westhaven Gold Secures $3.16 Million Investment for Growth

Updated Category News Views 128

Westhaven Gold Corp. Completes Strategic Private Placement Westhaven Gold Corp. (TSXV: WHN) has successfully closed a non-brokered private placement, raising a substantial $3.16 million to fuel its growth initiatives. This offering comprised the sale of units at a pivotal time for the company, allowing it to enhance its exploration and development capabilities. Details of...

Continue Reading
Revolutionizing Social Media: Alexis Ohanian and Kevin Rose Join Forces

Updated Category News Views 290

Reviving a Social Media Pioneer: Ohanian and Rose Unite In a surprising turn of events, social media titans Kevin Rose and Alexis Ohanian have teamed up to acquire the pioneering social platform, Digg. Both are recognized as early influencers in the tech industry, having co-founded some of the most notable platforms of the early web era. Now, their mission is clear: to...

Continue Reading
Exploring Innovation in CBA's Tech Ecosystem for 2024

Updated Category News Views 1337

Unveiling the Commonwealth Bank of Australia's Tech Innovations In the ever-evolving landscape of finance and technology, Commonwealth Bank of Australia (CBA) stands out as a leader. Their commitment to embracing digital transformation is not just a business strategy; it’s a comprehensive initiative that is reshaping how banking and financial services operate. The...

Continue Reading
Sheralven and Game On Team Up for Messi's Signature Fragrance

Updated Category News Views 167

Sheralven and Game On Join Forces for Messi Fragrance Launch In an exciting partnership that combines sports and beauty, Sheralven, a leader in the beauty industry, has teamed up with Game On Product Group to exclusively distribute the much-anticipated Messi Eau de Parfum in North America. This marks a significant collaboration as the fragrance is the first signature...

Continue Reading
CK Health Plus Secures Direct Selling License in Malaysia

Updated Category News Views 176

CK Health Plus Achieves Milestone in Malaysia CK Health Plus Sdn. Bhd., a subsidiary of EUDA Health Holdings Limited (NASDAQ: EUDA), has recently achieved a significant milestone by securing a Direct Selling License in Malaysia. This achievement reinforces the Company’s commitment to expanding its non-invasive healthcare offerings across Asia. Understanding the...

Continue Reading